Standard BioTools Past Earnings Performance
Past criteria checks 0/6
Standard BioTools's earnings have been declining at an average annual rate of -17%, while the Life Sciences industry saw earnings growing at 19.6% annually. Revenues have been declining at an average rate of 2.7% per year.
Key information
-17.0%
Earnings growth rate
-6.3%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | -2.7% |
| Return on equity | -45.7% |
| Net Margin | -70.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Standard BioTools makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 106 | -75 | 88 | 26 |
| 30 Sep 23 | 105 | -76 | 95 | -1 |
| 30 Jun 23 | 105 | -84 | 95 | 0 |
| 31 Mar 23 | 97 | -131 | 102 | 0 |
| 31 Dec 22 | 98 | -190 | 102 | 34 |
| 30 Sep 22 | 109 | -179 | 105 | 2 |
| 30 Jun 22 | 112 | -163 | 107 | 0 |
| 31 Mar 22 | 124 | -117 | 102 | 0 |
| 31 Dec 21 | 131 | -59 | 99 | 0 |
| 30 Sep 21 | 137 | -68 | 108 | 0 |
| 30 Jun 21 | 148 | -60 | 106 | 0 |
| 31 Mar 21 | 143 | -56 | 103 | 0 |
| 31 Dec 20 | 138 | -53 | 98 | 0 |
| 30 Sep 20 | 126 | -48 | 85 | 0 |
| 30 Jun 20 | 113 | -55 | 83 | 0 |
| 31 Mar 20 | 115 | -55 | 84 | 0 |
| 31 Dec 19 | 117 | -65 | 84 | 0 |
| 30 Sep 19 | 117 | -67 | 88 | 8 |
| 30 Jun 19 | 120 | -69 | 87 | 15 |
| 31 Mar 19 | 118 | -71 | 84 | 23 |
| 31 Dec 18 | 113 | -59 | 80 | 0 |
| 30 Sep 18 | 108 | -55 | 74 | 53 |
| 30 Jun 18 | 104 | -56 | 74 | 45 |
| 31 Mar 18 | 102 | -57 | 76 | 38 |
| 31 Dec 17 | 102 | -61 | 80 | 31 |
| 30 Sep 17 | 99 | -68 | 86 | 0 |
| 30 Jun 17 | 97 | -72 | 87 | 0 |
| 31 Mar 17 | 101 | -73 | 90 | 0 |
| 31 Dec 16 | 104 | -76 | 93 | 38 |
| 30 Sep 16 | 110 | -71 | 93 | 0 |
| 30 Jun 16 | 117 | -61 | 91 | 0 |
| 31 Mar 16 | 117 | -57 | 88 | 0 |
| 31 Dec 15 | 115 | -53 | 83 | 0 |
| 30 Sep 15 | 117 | -51 | 78 | 0 |
| 30 Jun 15 | 118 | -56 | 79 | 0 |
| 31 Mar 15 | 117 | -53 | 75 | 0 |
| 31 Dec 14 | 116 | -53 | 71 | 0 |
| 30 Sep 14 | 104 | -47 | 66 | 0 |
| 30 Jun 14 | 92 | -37 | 58 | 0 |
| 31 Mar 14 | 82 | -28 | 52 | 0 |
| 31 Dec 13 | 71 | -17 | 48 | 0 |
| 30 Sep 13 | 66 | -15 | 45 | 0 |
| 30 Jun 13 | 60 | -15 | 42 | 0 |
Quality Earnings: FLB is currently unprofitable.
Growing Profit Margin: FLB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FLB is unprofitable, and losses have increased over the past 5 years at a rate of 17% per year.
Accelerating Growth: Unable to compare FLB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FLB is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (0.4%).
Return on Equity
High ROE: FLB has a negative Return on Equity (-45.74%), as it is currently unprofitable.